Tactile Medical Announces Clinical Trial Results In Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy; The Secondary Endpoint Results Demonstrated Statistically Significant Improvements, Baseline To 52 Weeks, With Reductions In Limb Girth, Cellulitis Events, And Skin Hyperpigmentation
Portfolio Pulse from Benzinga Newsdesk
Tactile Systems Technology, Inc. (NASDAQ:TCMD) announced positive results from a clinical trial using their Flexitouch device for lymphedema treatment. The study showed significant improvements in limb girth, cellulitis events, and skin hyperpigmentation over 52 weeks.
September 25, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tactile Systems Technology's Flexitouch device showed significant clinical improvements in a 52-week study, potentially boosting investor confidence and stock price.
The positive clinical trial results for the Flexitouch device are likely to enhance the company's reputation and investor confidence, potentially leading to a short-term increase in TCMD's stock price. The study's publication in a peer-reviewed journal further validates the product's effectiveness.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100